Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Novel orally bioavailable piperidine derivatives as extracellular arginase inhibitors developed by a ring expansion.
Gzik A, Borek B, Chrzanowski J, Jedrzejczak K, Dziegielewski M, Brzezinska J, Nowicka J, Grzybowski MM, Rejczak T, Niedzialek D, Wieczorek G, Olczak J, Golebiowski A, Zaslona Z, Blaszczyk R. Gzik A, et al. Among authors: brzezinska j. Eur J Med Chem. 2024 Jan 15;264:116033. doi: 10.1016/j.ejmech.2023.116033. Epub 2023 Dec 10. Eur J Med Chem. 2024. PMID: 38096651
OATD-02 Validates the Benefits of Pharmacological Inhibition of Arginase 1 and 2 in Cancer.
Grzybowski MM, Stańczak PS, Pomper P, Błaszczyk R, Borek B, Gzik A, Nowicka J, Jędrzejczak K, Brzezińska J, Rejczak T, Güner-Chalimoniuk NC, Kikulska A, Mlącki M, Pęczkowicz-Szyszka J, Olczak J, Gołębiowski A, Dzwonek K, Dobrzański P, Zasłona Z. Grzybowski MM, et al. Among authors: brzezinska j. Cancers (Basel). 2022 Aug 17;14(16):3967. doi: 10.3390/cancers14163967. Cancers (Basel). 2022. PMID: 36010962 Free PMC article.
Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy.
Borek B, Nowicka J, Gzik A, Dziegielewski M, Jedrzejczak K, Brzezinska J, Grzybowski M, Stanczak P, Pomper P, Zagozdzon A, Rejczak T, Matyszewski K, Golebiowski A, Olczak J, Lisiecki K, Tyszkiewicz M, Kania M, Piasecka S, Cabaj A, Dera P, Mulewski K, Chrzanowski J, Kusmirek D, Sobolewska E, Magdycz M, Mucha L, Masnyk M, Golab J, Nowotny M, Nowak E, Napiorkowska-Gromadzka A, Pikul S, Jazwiec R, Dzwonek K, Dobrzanski P, Meyring M, Skowronek K, Iwanowski P, Zaslona Z, Blaszczyk R. Borek B, et al. Among authors: brzezinska j. Mol Cancer Ther. 2023 Jul 5;22(7):807-817. doi: 10.1158/1535-7163.MCT-22-0721. Mol Cancer Ther. 2023. PMID: 36939275
Association of ABO and Rhesus blood groups with severe outcomes from non-SARS-CoV-2 respiratory infection: A prospective observational cohort study in Bristol, UK 2020-2022.
Hathaway A, Qian G, King J, McGuinness S, Maskell N, Oliver J, Finn A, Danon L, Challen R, Toye AM, Hyams C; Avon CAP Research Group. Hathaway A, et al. Br J Haematol. 2024 Mar;204(3):826-838. doi: 10.1111/bjh.19234. Epub 2023 Nov 27. Br J Haematol. 2024. PMID: 38009561 Free PMC article.
Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom.
Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, King J, Morley A, Kinney J, Clout M, Oliver J, Gray S, Ellsbury G, Maskell N, Jodar L, Gessner B, McLaughlin J, Danon L, Finn A; AvonCAP Research Group. Hyams C, et al. Lancet Reg Health Eur. 2023 Feb;25:100556. doi: 10.1016/j.lanepe.2022.100556. Epub 2022 Dec 12. Lancet Reg Health Eur. 2023. PMID: 36530491 Free PMC article.
30 results